Cargando…
IMiDs for myeloma induced renal impairment
Autores principales: | Gavriatopoulou, Maria, Terpos, Evangelos, Dimopoulos, Meletios Athanasios |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6231459/ https://www.ncbi.nlm.nih.gov/pubmed/30464802 http://dx.doi.org/10.18632/oncotarget.26270 |
Ejemplares similares
-
IMiD-Free Interval and IMiDs Sequence: Which Strategy Is Better Suited for Lenalidomide-Refractory Myeloma?
por: Suzuki, Kazuhito, et al.
Publicado: (2023) -
Repurposing Immunomodulatory Imide Drugs (IMiDs) in Neuropsychiatric and Neurodegenerative Disorders
por: Jung, Yoo Jin, et al.
Publicado: (2021) -
The extended 4-year follow-up results of the ELOQUENT-2 trial
por: Gavriatopoulou, Maria, et al.
Publicado: (2019) -
Internal ribosome entry site of bFGF is the target of thalidomide for IMiDs development in multiple myeloma
por: Lien, I-Chia, et al.
Publicado: (2014) -
A New Generation of IMiDs as Treatments for Neuroinflammatory and Neurodegenerative Disorders
por: Kopp, Katherine O., et al.
Publicado: (2023)